1. Home
  2. Companies
  3. RHT
  4. Material Events

Resonance Health (ASX:RHT) — Material Events

ASX:RHT · 11 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 10 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Resonance Health Surges with Record Revenue and Breakthrough Tech TrialsMedium
Resonance Health reports record revenue, strong clinical trial progress, and new tech deployments
30 Jan 2026 ·Quarterly Activities & Cashflow Report ·85
Resonance Health Advances Non-Invasive Liver Fibrosis MRI Device Amid FY26 GrowthMedium
Resonance Health advances MRI Liver Fibrosis Device with FY26 portfolio update and webinar
9 June 2026 ·Investor Presentation ·85
Resonance Health Accelerates Growth with $17M FY26 Revenue TargetMedium
Resonance Health posts strong FY25 growth, guides $17M revenue for FY26
29 Aug 2025 ·Full Year Results & Guidance ·85
Resonance Health Lifts FY26 EBITDA Forecast by 30 Percent on Margin GainsMedium
Resonance Health upgrades FY26 EBITDA guidance by 30% amid margin expansion and operational growth
5 May 2026 ·Profit Guidance Upgrade ·85
Resonance Health Advances Clinical Trials and Secures Record SaMD ContractsMedium
Resonance Health reports positive cash flow, clinical trial progress, and record SaMD contracts
29 Oct 2025 ·Quarterly Activities & Cashflow Report ·80
Resonance Health Nears $13.8M Trial Completion with Record $10M SaMD PipelineMedium
Resonance Health reports strong cash flow, near completion of $13.8M clinical trial, and record $10M+ SaMD order pipeline
29 Apr 2026 ·Quarterly Activities & Cashflow Report ·80
Resonance Health Charts $17M Revenue Surge with AI-Driven Clinical ExpansionMedium
Resonance Health projects $17M revenue by FY26, driven by AI-enabled SaMD growth and global clinical trial expansion
13 Oct 2025 ·Investor Presentation ·80
Resonance Health Eyes $17M Revenue by FY26 with Strategic Market ExpansionMedium
Resonance Health projects strong revenue growth to $17M by FY26, maintains positive EBITDA guidance
13 Nov 2025 ·Annual General Meeting Presentation ·80
Resonance Health Expands Clinical Trials Amid $1.73M Loss in FY25Medium
Resonance Health FY25 revenue up 29% but posts $1.73M loss; expands clinical trials and launches new MRI fibrosis tool
29 Aug 2025 ·Preliminary Final Report ·75
Resonance Health Advances Clinical Trials and SaMD Contracts with Positive CashflowMedium
Resonance Health reports positive cashflow, key clinical trial milestones, and expansion of trial sites and SaMD contracts
31 July 2025 ·Quarterly Activities & Cashflow Report ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.